Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study ummary Background Hong Kong maintained low circulation of SARS-CoV-2 until a major community epidemic of the omicron (B.1.1.529) sublineage BA.2 began in January, 2022. Both mRNA (BNT162b2 [Fosun Pharma-BioNTech]) and inactivated CoronaVac (Sinovac, Beijing, China) vaccines are widely available; however, vaccination coverage has been low, particularly in older adults aged 70 years or older. We aimed to assess vaccine effectiveness in this predominantly infection-naive population. Methods In this observational study, we used individual-level case data on mild or moderate, severe or fatal, and fatal disease in patients hospitalised with COVID-19 along with census information and coverage data of BNT162b2 and CoronaVac. We used a negative binomial model, adjusting for age, sex, and calendar day to estimate vaccine effectiveness of one, two, and three doses of both BNT162b2 and CoronaVac vaccines, and relative effectiveness by number of doses and vaccine type. Findings Between Dec 31, 2020, and March 16, 2022, 13·2 million vaccine doses were administered in Hong Kong''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''s 7·4-million population. We analysed data from confirmed cases with mild or moderate (n=5566), severe or fatal (n=8875), and fatal (n=6866) COVID-19. Two doses of either vaccine protected against severe disease and death within 28 days of a positive test, with higher effectiveness among adults aged 60 years or older with BNT162b2 (vaccine effectiveness 89·3% [95% CI 86·6–91·6]) compared with CoronaVac (69·9% [64·4–74·6]). Three doses of either vaccine offered very high levels of protection against severe or fatal outcomes (97·9% [97·3–98·4]). Interpretation Third doses of either BNT162b2 or CoronaVac provide substantial additional protection against severe COVID-19 and should be prioritised, particularly in older adults older than 60 years and others in high-risk populations who received CoronaVac primary schedules. Longer follow-up is needed to assess duration of protection across different vaccine platforms and schedules.
十四亿人有选择不在无疫苗情况下面对高毒性毒株三年。
90%疫苗覆盖后开放接触降低毒性嗜肺性的毒株。
Facts。
三针灭活疫苗防重症防死亡和mRNA无差别。即使在死亡率最高的80岁以上组也降低死亡率97%以上,
数据发在柳叶刀。
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00345-0/fulltext
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
ummary Background Hong Kong maintained low circulation of SARS-CoV-2 until a major community epidemic of the omicron (B.1.1.529) sublineage BA.2 began in January, 2022. Both mRNA (BNT162b2 [Fosun Pharma-BioNTech]) and inactivated CoronaVac (Sinovac, Beijing, China) vaccines are widely available; however, vaccination coverage has been low, particularly in older adults aged 70 years or older. We aimed to assess vaccine effectiveness in this predominantly infection-naive population. Methods In this observational study, we used individual-level case data on mild or moderate, severe or fatal, and fatal disease in patients hospitalised with COVID-19 along with census information and coverage data of BNT162b2 and CoronaVac. We used a negative binomial model, adjusting for age, sex, and calendar day to estimate vaccine effectiveness of one, two, and three doses of both BNT162b2 and CoronaVac vaccines, and relative effectiveness by number of doses and vaccine type. Findings Between Dec 31, 2020, and March 16, 2022, 13·2 million vaccine doses were administered in Hong Kong''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''s 7·4-million population. We analysed data from confirmed cases with mild or moderate (n=5566), severe or fatal (n=8875), and fatal (n=6866) COVID-19. Two doses of either vaccine protected against severe disease and death within 28 days of a positive test, with higher effectiveness among adults aged 60 years or older with BNT162b2 (vaccine effectiveness 89·3% [95% CI 86·6–91·6]) compared with CoronaVac (69·9% [64·4–74·6]). Three doses of either vaccine offered very high levels of protection against severe or fatal outcomes (97·9% [97·3–98·4]). Interpretation Third doses of either BNT162b2 or CoronaVac provide substantial additional protection against severe COVID-19 and should be prioritised, particularly in older adults older than 60 years and others in high-risk populations who received CoronaVac primary schedules. Longer follow-up is needed to assess duration of protection across different vaccine platforms and schedules.
是的,我妈2021年秋天来美国,打了三针摩德纳,10月打了二价疫苗回国 周围那么多人都得新冠了,老妈目前还挺住了
我毫不怀疑如果现在缺粮,他们也会拒绝粮的,并且引用一堆典故,比如不食周粟之类的。然后说美国如何阴谋制造粮食危机。
你这个小粉红说说看,中共不迷信疫苗,为啥还强迫老百姓都打灭活疫苗呢? 当然,一个二傻子也能找出学霸的茬
美国人打了疫苗后,重症率和死亡率大幅下降。不光是美国的数据,其他国家数据也是如此。 当然你可以只看国内新闻不看国外的数据。只是国内老人们比较可怜。连选择疫苗和药物的机会都没有。
版上大妈说了无数遍,灭活不可怕,😨的是把塑料打入体内,以后要得各种病。
首先不要随意叫人小粉红,可没人叫你1450, 5分什么的。 mRNA不好,并不说明灭活疫苗好。只是用传统的疫苗生产方法研究可行的法案罢了·。最起码灭活疫苗用了有百年了吧。各种referene比mRNA多多了。就算没有效果,副作用之类也多少有个expectation. 你强推mRNA, 为什么别人不能推灭活?结果谁也别笑话谁?
很多愚昧的人对于新生事物都是这种态度。就如同当年那些反对汽车飞机智能手机的人一样。
据说中国其实已经不会缺粮了,杂交水稻可以让中国人饿不死。不过以现在中国人的尿性,让他们只吃杂交水稻过日子估计比60年前吃树根树皮叫的还响。而且已经全球化了,中国又不是最穷的大国,大不了出国去霍霍更低端的国家比如泰国据说已经被中国霍霍的不像样了。
新冠真的也分裂了很多海内外的家人朋友。
会瑞ceo打了4针mrna, 结果阳了两次
美国人自己都不打这个疫苗, 到现在, 第 2针注射率都不到60%。
这个疫苗还不如paxlovid可信3。
这个版上大明白特别多,新冠的时候懂疫苗,流行病,病毒传播,美国选举的时候懂美国宪法,政治。俄乌战争的时候懂军事。仔细看看都是一波人。立场决定观点。屁股决定脑袋。总之中国赢就对了,懂王就是这么来的吧。估计都是川粉。
关键是十月打了二阶疫苗,到12月正式保护能力强的时期。中国的大部分第三剂疫苗都是一年前打的,防护能力当然受影响。
比较疫苗的有效率是很复杂的事情,变量太多
这和汽车飞机可完全不一样,这是直接进入人体了。找类比也应该用海洛因的例子
国内35亿剂次的疫苗接种量,只有国产疫苗能保证及时供应,况且国产疫苗的效果并不差,安全性也更高。 就算引进了国外疫苗,供应也跟不上,到时候造成分配不均,会招来更多的黑。 国外疫苗公司怕是眼红,没有赚到国内疫苗钱,疯狂贬低国产疫苗,什么生理盐水,国产疫苗起反作用的言论都出来了,他们越是这样越让人反感; 虽然我也认为mRNA疫苗效果可能更好,但我支持中国政府不引进,国产疫苗能满足中国需求,符合中国国情。
支持你。